6533b873fe1ef96bd12d5760

RESEARCH PRODUCT

Interferon α interferes with immunological tolerance.

Christian BeckerTobias BoppKerstin Steinbrink

subject

tolerancebusiness.industrymedicine.medical_treatmentImmunologyImmunotherapeutic agentCancerNK cellsmedicine.diseasePDEregulatory T cellsIfn alphaOncologyCancer immunotherapyInterferon αcAMPImmunologymedicineImmunology and AllergycancerIFN-alphabusinessAuthor's ViewFunction (biology)

description

The ability of regulatory T cells (Tregs) to promote immunological tolerance represents an important obstacle in cancer immunotherapy. We have recently discovered that the clinically established immunotherapeutic agent interferon α (IFNα) inactivates the suppressive functions of human Tregs. Here, we outline the mechanisms whereby IFNα mediates this important function and discuss its therapeutic implications for cancer immunotherapy.

yearjournalcountryeditionlanguage
2013-12-01Oncoimmunology
10.4161/onci.27528https://pubmed.ncbi.nlm.nih.gov/24575381